Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Study of AMX0035 in ALS
NCT04987671Phase 2Unknown
- Sponsor
- Amylyx Pharmaceuticals
- Start
- Aug 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sodium phenylbutyrate in amyotrophic lateral sclerosis (ALS), sponsored by Amylyx Pharmaceuticals. Status: unknown.
02
Drugs
sodium phenylbutyrate
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04987671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04987671.